Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 5/20 | 0.46 |
| ▸ | ACE | P12821 | 1/20 | 0.46 |
| ▸ | CPA1 | P15085 | 1/20 | 0.46 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | FAAH | O00519 | 2/20 | 0.39 |
| ▸ | LTA4H | P09960 | 4/20 | 0.39 |
| ▸ | ANPEP | P15144 | 1/20 | 0.39 |
| ▸ | ECE1 | P42892 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31106917 | 1.00 | MME (0.46) | MMEACECPA1ACE2SMN1; SMN2 | |
| SCHEMBL3087602 | 1.00 | MME (0.46) | MMEACECPA1ACE2SMN1; SMN2 | |
| SCHEMBL3087607 | 1.00 | MME (0.46) | MMEACECPA1ACE2SMN1; SMN2 | |
| SCHEMBL10621114 | 1.00 | MME (0.46) | MMEACECPA1ACE2SMN1; SMN2 | |
| SCHEMBL30905102 | 1.00 | MME (0.46) | MMEACECPA1ACE2SMN1; SMN2 | |
| SCHEMBL24323603 | 1.00 | MME (0.46) | MMEACECPA1ACE2SMN1; SMN2 | |
| SCHEMBL31106850 | 1.00 | MME (0.46) | MMEACECPA1ACE2SMN1; SMN2 | |
| SCHEMBL30178287 | 1.00 | MME (0.46) | MMEACECPA1ACE2SMN1; SMN2 | |
| SCHEMBL3145911 | 0.92 | SMN1; SMN2 (0.50) | MMEACECPA1ACE2SMN1; SMN2 | |
| SCHEMBL783990 | 0.92 | SMN1; SMN2 (0.50) | MMEACECPA1ACE2SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 345 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250270258-A1 | BICYCLIC PEPTIDYL INHIBITORS | OHIO STATE INNOVATION FOUNDATION | 2025-08-28 | — | — | US | claimed |
| US-12281181-B2 | Bicyclic peptidyl inhibitors | OHIO STATE INNOVATION FOUNDATION (US) | 2025-04-22 | — | — | US | claimed |
| WO-2025034601-A1 | AAV GENE THERAPY FOR ALPHA-1 ANTITRYPSIN DEFICIENCY | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2025-02-13 | — | — | WO | claimed |
| US-20240392304-A1 | CIRCULAR RNA AND PREPARATION METHOD THEREOF | CENTER FOR EXCELLENCE IN MOLECULAR CELL SCIENCE, CHINESE ACADEMY OF SCIENCES (CN) | 2024-11-28 | — | — | US | claimed |
| WO-2024233366-A2 | MODIFIED CAS9-IID NUCLEASES AND USES THEREOF | Aera Therapeutics, Inc. (US) | 2024-11-14 | — | — | WO | claimed |
| WO-2024206825-A2 | MODIFIED ISCB NUCLEASES, MODIFIED GUIDE RNAS, AND USES THEREOF | Aera Therapeutics, Inc. (US) | 2024-10-03 | — | — | WO | claimed |
| US-20240263173-A1 | HIGH-THROUGHPUT PRECISION GENOME EDITING IN HUMAN CELLS | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2024-08-08 | — | — | US | claimed |
| EP-4405480-A1 | CIRCULAR RNA AND PREPARATION METHOD THEREOF | Center for Excellence in Molecular Cell Science, Chinese Academy of Sciences (CN) | 2024-07-31 | — | — | EP | claimed |
| EP-4384616-A2 | HIGH-THROUGHPUT PRECISION GENOME EDITING IN HUMAN CELLS | The Board of Trustees of the Leland Stanford Junior University (US) | 2024-06-19 | — | — | EP | claimed |
| CN-117625631-A | Zebra fish nxhl marker gene and application thereof | 广西壮族自治区人民医院 | 2024-03-01 | — | — | CN | claimed |
| US-20230349001-A1 | BIOMOLECULAR CHARACTERISTIC IDENTIFICATION METHOD AND SYSTEM THEREOF FOR TAIWAN TILAPIA STRAINS | NATIONAL TAIWAN OCEAN UNIVERSITY (TW) | 2023-11-02 | — | — | US | claimed |
| US-20230322859-A1 | BICYCLIC PEPTIDYL INHIBITORS | OHIO STATE INNOVATION FOUNDATION | 2023-10-12 | — | — | US | claimed |
| US-11673919-B2 | Bicyclic peptidyl inhibitors | OHIO STATE INNOVATION FOUNDATION (US) | 2023-06-13 | — | — | US | claimed |
| WO-2023046153-A1 | CIRCULAR RNA AND PREPARATION METHOD THEREOF | CENTER FOR EXCELLENCE IN MOLECULAR CELL SCIENCE, CHINESE ACADEMY OF SCIENCES (CN) | 2023-03-30 | — | — | WO | claimed |
| WO-2023019164-A2 | HIGH-THROUGHPUT PRECISION GENOME EDITING IN HUMAN CELLS | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2023-02-16 | — | — | WO | claimed |
| US-20220281920-A1 | BICYCLIC PEPTIDYL INHIBITORS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-09-08 | — | — | US | claimed |
| US-11339192-B2 | Bicyclic peptidyl inhibitors | OHIO STATE INNOVATION FOUNDATION (US) | 2022-05-24 | — | — | US | claimed |
| US-20260132463-A1 | METHODS OF ENRICHING TARGETED NUCLEIC ACID, IDENTIFYING OFF-TARGET AND EVALUATING GENE EDITING EFFICIENCY | GENEDITBIO LTD (CN) | 2026-05-14 | — | — | US | disclosed |
| CN-114047330-A | Turn-on doxycycline specificity homogeneous phase detection system based on FRET and application thereof | 北京维德维康生物技术有限公司 | 2022-02-15 | — | — | CN | disclosed |
| CN-106661580-B | Antisense oligonucleotides for treating pompe disease | 鹿特丹伊拉斯谟大学医疗中心 | 2022-02-15 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220281920-A1 | BICYCLIC PEPTIDYL INHIBITORS | NFKBIA, IKBKG, NFRKB | MME 3591/4885ACE 4664/4885CPA1 2173/4885 |
| US-11673919-B2 | Bicyclic peptidyl inhibitors | NFKBIA, IKBKG, NFRKB | MME 3591/4885ACE 4664/4885CPA1 2173/4885 |
| US-20230322859-A1 | BICYCLIC PEPTIDYL INHIBITORS | NFKBIA, IKBKG, NFRKB | MME 3591/4885ACE 4664/4885CPA1 2173/4885 |
| US-12281181-B2 | Bicyclic peptidyl inhibitors | NFKBIA, IKBKG, NFRKB | MME 3591/4885ACE 4664/4885CPA1 2173/4885 |
| US-20250270258-A1 | BICYCLIC PEPTIDYL INHIBITORS | NFKBIA, IKBKG, NFRKB | MME 3591/4885ACE 4664/4885CPA1 2173/4885 |
| US-20260132463-A1 | METHODS OF ENRICHING TARGETED NUCLEIC ACID, IDENTIFYING OFF-TARGET AND EVALUATING GENE EDITING EFFICIENCY | ADAR, ADA, RNGTT | MME 3777/4885ACE 3218/4885CPA1 1352/4885 |
| US-11339192-B2 | Bicyclic peptidyl inhibitors | NFKBIA, IKBKG, NFRKB | MME 3591/4885ACE 4664/4885CPA1 2173/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.